89bio, Inc. (ETNB)
NASDAQ: ETNB · Real-Time Price · USD
6.07
+0.18 (2.97%)
Apr 17, 2025, 4:00 PM EDT - Market closed
89bio Employees
89bio had 93 employees as of December 31, 2024. The number of employees increased by 23 or 32.86% compared to the previous year.
Employees
93
Change (1Y)
23
Growth (1Y)
32.86%
Revenue / Employee
n/a
Profits / Employee
-$3,947,086
Market Cap
884.66M
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 400,000 |
Johnson & Johnson | 138,100 |
Thermo Fisher Scientific | 125,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 92,900 |
Novartis AG | 75,883 |
ETNB News
- 6 weeks ago - 89bio to Participate in the Leerink Partners Global Healthcare Conference - GlobeNewsWire
- 7 weeks ago - 89bio Reports Fourth Quarter and Full Year 2024 Financial Results and Corporate Updates - GlobeNewsWire
- 2 months ago - 89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 2 months ago - 89bio's Pegozafermin Is Now Gaining Momentum - Seeking Alpha
- 2 months ago - 89bio, Inc. Announces Pricing of $250.0 Million Public Offering of Common Stock and Pre-Funded Warrants - GlobeNewsWire
- 2 months ago - 89bio, Inc. Announces Proposed Underwritten Public Offering of Common Stock and Pre-Funded Warrants - GlobeNewsWire
- 3 months ago - 89bio: Advancement Of Pegozafermin For SHTG Is Another Path Forward - Seeking Alpha
- 5 months ago - 89bio Presents New Analyses Evaluating Pegozafermin and Potential Benefit of Non-Invasive Tests from the ENLIVEN Phase 2b Trial in MASH Patients at AASLD The Liver Meeting® 2024 - GlobeNewsWire